We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
From May 2019 to May 2024
By Razak Musah Baba
LONDON--GlaxoSmithKline PLC (GSK.LN) said Tuesday that it has received approval from the European Commission to widen the application of its drug Volibris to treat pulmonary arterial hypertension.
The pharmaceutical firm said the European Commission has approved a variation of the drug to expand the current therapeutic indication for Volibris (ambrisentan). The drug can now be used as part of a combination treatment for patients with pulmonary arterial hypertension.
PAH is a disease characterized by constriction of the blood vessels in the lungs leading to high pulmonary arterial pressures.
Shares at 1100 GMT down 0.14 pence, or 1.04%, at GBP13.31, valuing the company at GBP64.78 billion.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 24, 2015 06:32 ET (11:32 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
